Bruton's Tyrosine Kinase—Going Beyond the B Cell
Immunology · 2026-08 · 178 (4) · 545-560
DOI: 10.1111/imm.70126 ↗Abstract
ABSTRACT Bruton's Tyrosine Kinase (BTK) is a cytoplasmic kinase essential for B cell‐mediated signalling, yet has also received recent recognition as a direct regulator of myeloid cell function. Beyond its established role in B cell malignancies, BTK influences receptor‐driven activation in monocytes, macrophages, microglia, granulocytes, and other organ‐specific macrophages by influencing key molecular pathways involved in phagocytosis, inflammatory‐mediated signalling, and cell metabolism (e.g., NFκB, STAT3, and NLRP3). BTK inhibitors (BTKis) were initially developed and approved to treat B cell‐related cancers, however, they have also demonstrated significant therapeutic/clinical efficacy in autoimmune, allergic, and immune‐driven neuroinflammatory disorders, including rheumatoid arthritis, IgA nephropathy, multiple sclerosis, and chronic spontaneous urticaria. This review specifically addresses, compares, and summarises how BTK inhibition within distinct myeloid‐derived cell subsets alters inflammatory‐related phenotypes and functions within these cells. Together, providing cell‐specific insights into BTK as a central regulator of innate immunity and myeloid cell function may help generate significant translational potential for BTKis in multiple inflammatory‐mediated diseases.
EUVIMED